FDA milestone puts Neurocrine Biosciences in focus

The FDA’s acceptance of Neurocrine Biosciences (NBIX) Investigational New Drug application for NBI-1117567 clears the way for a Phase 2 trial in Alzheimer’s cognition and triggers a US$10 million payment to partner Nxera Pharma.

Despite the FDA milestone, Neurocrine Biosciences’ recent share price momentum has cooled, with the 30 day share price return down 14.79%, even as the year to date share price return is up 9.57% and the 5 year total shareholder return is 60.70%.

Capture how Neurocrine Biosciences fits alongside other neurology and biotech ideas by scanning a curated 19 high quality undiscovered gems that may be flying under most investors' radar.

Neurocrine Biosciences now trades at a sizeable discount to both analyst targets and one intrinsic value estimate, even after a strong multiyear run and a recent pullback. Does that gap reflect opportunity or justified caution?

Most Popular Narrative: 27.7% Undervalued

On this framework, Neurocrine Biosciences’ fair value sits around $213 per share versus the recent $154.06 close, which is a sizeable narrative gap for investors to unpack.

A broad, late-stage and diversified CNS pipeline, including multiple Phase III programs targeting major depressive disorder and schizophrenia, leverages advances in precision medicine and increases visibility for future earnings, supporting potential future valuation multiple expansion.

Read the complete narrative. Read the complete narrative..

Want to know what justifies that higher fair value for Neurocrine Biosciences? The narrative leans heavily on compound earnings growth, richer margins, and a punchy future P/E multiple. Curious which specific targets and assumptions need to line up to support that view? The full story joins those moving parts into one valuation blueprint.

Result: Fair Value of $213 (UNDERVALUED)

However, that gap can quickly close if Neurocrine Biosciences faces tougher payer pushback on INGREZZA pricing or if key late stage CNS trials disappoint and weaken the pipeline story.

Another view on Neurocrine Biosciences’ valuation

On simple earnings multiples, Neurocrine Biosciences looks less clear cut. The stock trades on a P/E of 22.2x, higher than the US Biotechs industry at 16.9x, yet below an estimated fair ratio of 25x. Is that a reasonable premium or a sign expectations are already loaded?

Investors weighing this relative pricing against the earlier fair value estimate may want to test which story they trust more: the cash flow driven view or the earnings multiple view, before making any portfolio moves. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and caution around Neurocrine Biosciences feels familiar, take a closer look now and shape your own view before sentiment moves. To see the specific factors that investors appear most upbeat about, review the 4 key rewards.

Looking for more investment ideas beyond Neurocrine Biosciences?

If Neurocrine Biosciences has sharpened your attention on valuation and risk, do not stop here. Use the screener to spot other mispriced or overlooked opportunities.

• Focus on quality by reviewing companies with resilient finances and dependable track records through the 74 resilient stocks with low risk scores.
• Target potential value by scanning the 44 high quality undervalued stocks that combine solid fundamentals with appealing pricing.
• Strengthen your income stream by checking companies in the 12 dividend fortresses that offer higher yields with an emphasis on durability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.